Concurrent Weekly Docetaxel Chemotherapy in Combination with Radiotherapy for Stage III and IVA-B Nasopharyngeal Carcinoma

Wei, Wei-Hong,Cai, Xiu-Yu,Xu, Tao,Zhang, Guo-Yi,Wu, Yong-Feng,Feng, Wei-Neng,Lin, Li,Deng, Yan-Ming,Lu, Qiu-Xia,Huang, Zhe-Li Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.3

Background and Purpose: Cisplatin is the most common chemotherapeutic agent for loco-regionally advanced nasopharyngeal carcinoma (NPC); however, toxicity is a limiting factor for some patients. We retrospectively compared the efficacy and toxicity of weekly docetaxel-based and cisplatin-based concurrent chemoradiotherapy in loco-regionally advanced NPC. Methods and Materials: Eighty-four patients with Stage III and IVA-B NPCs, treated between 2007 and 2008, were retrospectively analyzed. Thirty received weekly docetaxel-based concurrent chemotherapy, and 43 were given weekly cisplatin-based concurrent chemotherapy. Radiotherapy was administered using a conventional technique (seven weeks, 2.0 Gy per fraction, total dose 70-74 Gy) with 6-8 Gy boosts for some patients with locally advanced disease. Results: Median follow-up time was 42.3 months (range, 8.6-50.8 months). There were no significant differences in the 3-year loco-regional failure-free survival (85.6% vs. 92.3%; p=0.264), distant failure-free survival (87.0% vs. 92.5%; p=0.171), progression-free survival (85.7% vs. 88.4%; p=0.411) or overall survival (86.5% vs. 92.5%, p=0.298) of patients treated concurrently with docetaxel or cisplatin. Severe toxicity was not common in either group. Conclusions: Weekly docetaxel-based concurrent chemoradiotherapy is potentially effective and has a tolerable toxicity; however, further investigations are required to determine if docetaxel is superior to cisplatin for advanced stage NPC.

Validation of the Chinese Version of Penn Alcohol Craving Scale for Patients With Alcohol Use Disorder

Yu-Yu Ko,Su-Chen Fang,Wei-Chien Huang,Ming-Chyi Huang,Hu-Ming Chang 대한신경정신의학회 2024 PSYCHIATRY INVESTIGATION Vol.21 No.2

Objective The Penn Alcohol Craving Scale (PACS) is a five-item, single-dimension questionnaire that is used to measure a patient’s alcohol craving. We sought to develop the Chinese version of the PACS (PACS-C) and assess its reliability and validity.Methods A total of 160 Taiwanese patients with alcohol use disorder were enrolled in this study. The internal consistency and concurrent validity of the PASC-C with the visual analogue scale (VAS) for craving, the Yale–Brown Obsessive Compulsive Scale for heavy drinking (YBOCS-hd), and the Severity of Alcohol Dependence Questionnaire (SADQ) were assessed. The test–retest reliability of the PASC-C was evaluated 1 day after the baseline measurements. Confirmatory factor analysis (CFA) was performed to examine the psychometric properties of the PACS-C.Results The PACS-C exhibited good internal consistency (Cronbach’s α=0.95) and test–retest reliability (r=0.97). This scale showed high correlations with the VAS (r=0.81) and YBOCS-hd (r=0.81 and 0.79 for the obsession and compulsion subscales, respectively), and moderate correlation with the SADQ-C (r=0.47). Furthermore, CFA results revealed that the PACS-C had good fit indices under various models.Conclusion The PACS-C appears to be a reliable and valid tool for assessing alcohol craving in patients with alcohol use disorder in Taiwan.

An Improved Atomization Model with Size Distribution of Droplets Shed From Y-Jet Nozzles

( Ming Chuan Zhang ),( Yu Bao Song ),( Yu Gui Zhou ),( Bo Hong Shi ),( Juan Yu ),( Wei Dong Fan ) 한국액체미립화학회 2001 한국액체미립화학회 학술강연회 논문집 Vol.2001 No.-

Interleukin-20 targets podocytes and is upregulated in experimental murine diabetic nephropathy

Yu-Hsiang Hsu,Hsing-Hui Li,Junne-Ming Sung,Wei-Yu Chen,Ya-Chin Hou,Yun-Han Weng,Wei-Ting Lai,Chih-Hsing Wu,Ming-Shi Chang 생화학분자생물학회 2017 Experimental and molecular medicine Vol.49 No.-

Interleukin (IL)-20, a proinflammatory cytokine of the IL-10 family, is involved in acute and chronic renal failure. The aim of this study was to elucidate the role of IL-20 during diabetic nephropathy development. We found that IL-20 and its receptor IL-20R1 were upregulated in the kidneys of mice and rats with STZ-induced diabetes. In vitro, IL-20 induced MMP-9, MCP-1, TGF-β1 and VEGF expression in podocytes. IL-20 was upregulated by hydrogen peroxide, high-dose glucose and TGF-β1. In addition, IL-20 induced apoptosis in podocytes by activating caspase-8. In STZ-induced early diabetic nephropathy, IL-20R1-deficient mice had lower blood glucose and serum BUN levels and a smaller glomerular area than did wild-type controls. Anti-IL-20 monoclonal antibody (7E) treatment reduced blood glucose and the glomerular area and improved renal functions in mice in the early stage of STZ-induced diabetic nephropathy. ELISA showed that the serum IL-20 level was higher in patients with diabetes mellitus than in healthy controls. The findings of this study suggest that IL-20 induces cell apoptosis of podocytes and plays a role in the pathogenesis of early diabetic nephropathy.

A Novel Transparent Microwave Thin Film Coating Technique Applied to Dual‑Band Antennas

Yu-Ming Lin,Hung-Wei Wu,Yung-Wei Chen,Cheng-Yuan Hung,Shoou-Jinn Chang,Yan-Kuin Su 대한금속·재료학회 2019 ELECTRONIC MATERIALS LETTERS Vol.15 No.6

In this paper, we propose a novel transparent microwave thin film coating technique and discuss its application in planardual-band antennas (0.9/5.55 GHz). We developed a new process for activating the nano-alignment thin film from high tolow resistivity (from 1.96 to 1.29 × 10−4 Ω cm) and from partial to full transparency (from 55 to 83% transmittance) within150 s. The platform of the activation process comprises a periodic electrode, an optical microscope, and an alternating currentsignal generator. The periodic electrode can effectively rearrange the nano-alignment thin film into an ordered arrangement,which enhances the properties of the thin film in the microwave frequency range. A high-transparency and low-resistivitydual-band antenna is designed and fabricated using the proposed microwave thin film coating technique. The dual-bandantenna has operating bandwidths of 740–960 and 5030–7030 MHz and potential applications in transparent electronicssuch as wearable devices and intelligent cars.

Enhanced Performance of Pseudo-Bilayer Organic Photovoltaic Devices via Small Molecule Doping

Syu, Yu-Wei,Huang, Peng-Yi,Li, Husan-De,Hsu, Ching-Ling,Chiu, Kuan-Cheng,Kim, Choongik,Chen, Ming-Chou,Chao, Yu-Chiang American Chemical Society 2014 The Journal of Physical Chemistry Part C Vol.118 No.19

<P>Controlling both the film crystallinity of the active layer for better charge transport and the interdiffusion between donor and acceptor materials for optimal bicontinuous networks is essential in producing pseudo-bilayer polymer solar cells. In this work, we investigated the influence of a doping solution-processable small molecule with high carrier mobility, 5,11-bis(triethylsilylethynyl) anthradithiophene (TES-ADT), on the performance of pseudo-bilayer polymer solar cells made of an underlayer of poly(3-hexylthiophene) (P3HT) and an upper layer of [6,6]-phenyl-C61-butyric acid methyl ester (PCBM). By analysis of the X-ray diffraction and UV–vis absorbance spectra of P3HT:TES-ADT blend films it was demonstrated that the film crystallinity was enhanced by TES-ADT doping in the P3HT underlayer. The hole mobility extracted from the current density–voltage curves of hole-only devices based on P3HT:TES-ADT demonstrated an optimized value with proper TES-ADT doping and thermal annealing. An intermixed photoactive layer was observed for the annealed device, indicating the occurrence of interdiffusion with a large interfacial area. With improved film crystallinity and interdiffusion, the optimal device performance was obtained when 5% TES-ADT was blended with P3HT and a thermal annealing treatment at 150 °C for 1 min was conducted. At that optimal condition, the mean crystallite size was increased by 35%, and hence the enhancement of 8% and 14% in power conversion efficiency and short-circuit current density was observed, respectively.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/jpccck/2014/jpccck.2014.118.issue-19/jp502331x/production/images/medium/jp-2014-02331x_0007.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/jp502331x'>ACS Electronic Supporting Info</A></P>

No Association Between MTHFR A1298C Gene Polymorphism and Head and Neck Cancer Risk: A Meta-analysis Based on 9,952 Subjects

Niu, Yu-Ming,Shen, Ming,Li, Hui,Ni, Xiao-Bing,Zhou, Juan,Zeng, Xian-Tao,Leng, Wei-Dong,Wu, Ming-Yue Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.8

Objective: Findings for associations between the methylenetetrahydrofolate reductase (MTHFR) A1298C gene polymorphism and head and neck cancer risk have been conflicting. We therefore performed a meta-analysis to derive a more precise relationship. Methods: Ten published case-control studies were collected and odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association between MTHFR A1298C polymorphism and head and neck cancer risk. Sensitivity analysis and publication bias assessment also were performed to guarantee the statistical power. Results: Overall, no significant association between MTHFR A1298C polymorphism and head and neck cancer risk was found in this meta-analysis (C vs. A: OR=1.04, 95%CI=0.87-1.25, P=0.668, Pheterogeneity<0.001; CC vs. AA: OR=1.07, 95%CI=0.70-1.65, P=0.748, $P_{heterogeneity}<0.001$; AC vs. AA: OR=1.06, 95%CI=0.88-1.27, P=0.565, $P_{heterogeneity}<0.001$; CC+AC vs. AA: OR=1.06, 95%CI=0.86-1.30, P=0.571, $P_{heterogeneity}<0.001$; CC vs. AA+AC: OR=1.02, 95%CI=0.69-1.52, P=0.910, $P_{heterogeneity}<0.001$). Similar results were also been found in succeeding analysis of HWE and stratified analysis of ethnicity. Conclusion: In conclusion, our meta-analysis demonstrates that MTHFR A1298C polymorphism may not be a risk factor for developing head and neck cancer.

Association between Pax8-PPARγ1 Rearrangement and Follicular Thyroid Cancer: a Meta-Analysis

Li, Hang-Yu,Xie, Zhi-Hao,Xu, Cong-Hui,Pu, Mei-Ling,Chen, Zi-Yan,Yu, Miao,Wang, Heng-Shu,Zhou, Chen-Ming,Pu, Chao-Yu,Liu, Wei Asian Pacific Journal of Cancer Prevention 2016 Asian Pacific journal of cancer prevention Vol.17 No.9

Background: Pax8 and peroxisome proliferator-activated receptor gamma 1 gene (Pax8-$PPAR{\gamma}1$) are important factors in tumors. Several studies have suggested that follicular thyroid cancer may arise from Pax8- $PPAR{\gamma}1$ rearrangement. In order to have a better understanding of the association between Pax8-$PPAR{\gamma}1$ rearrangement and follicular thyroid cancer, we conducted the presenmt meta-analysis. Materials and Methods: The information was extracted from PubMed, EMBASE and Web of Science. Statistic analysis was performed with Stata12.0 software. Odds ratios (ORs) were calculated using a fixed-effects model. We also performed heterogeneity and publication bias analyses. Results: Nine studies including 198 follicular thyroid cancer patients and 268 controls were considered eligible. The frequency of Pax8-$PPAR{\gamma}1$ rearrangement was significantly higher in the follicular thyroid cancer group than in the control group, with a pooled OR of 6.63 (95%CI=3.50-12.7). In addition, through subgroup analysis, the OR between Pax8-$PPAR{\gamma}1$ rearrangement and follicular thyroid cancer was 6.04 (95%CI = 3.18-11.5) when using benign tumor tissues as controls. The OR for the method subgroup was 9.99 (95% CI =4.86-20.5) in the RT-PCR. Conclusions: The final results demonstrated that Pax8-$PPAR{\gamma}1$ rearrangement has significant association with follicular thyroid cancer.

Rapid and Efficient Detection of 16SrI Group Areca Palm Yellow Leaf Phytoplasma in China by Loop-Mediated Isothermal Amplification

Shao-shuai Yu,Hai-yan Che,Sheng-jie Wang,Cai-li Lin,Ming-xing Lin,Wei-wei Song,Qing-hua Tang,Wei Yan,Wei-quan Qin 한국식물병리학회 2020 Plant Pathology Journal Vol.36 No.5

Areca palm yellow leaf (AYL) disease caused by the 16SrI group phytoplasma is a serious threat to the development of the Areca palm industry in China. The 16S rRNA gene sequence was utilized to establish a rapid and efficient detection system efficient for the 16SrI-B subgroup AYL phytoplasma in China by loopmediated isothermal amplification (LAMP). The results showed that two sets of LAMP detection primers, 16SrDNA-2 and 16SrDNA-3, were efficient for 16SrIB subgroup AYL phytoplasma in China, with positive results appearing under reaction conditions of 64oC for 40 min. The lowest detection limit for the two LAMP detection assays was the same at 200 ag/μl, namely approximately 53 copies/μl of the target fragments. Phytoplasma was detected in all AYL disease samples from Baoting, Tunchang, and Wanning counties in Hainan province using the two sets of LAMP primers 16SrDNA-2 and 16SrDNA-3, whereas no phytoplasma was detected in the negative control. The LAMP method established in this study with comparatively high sensitivity and stability, provides reliable results that could be visually detected, making it suitable for application and research in rapid diagnosis of AYL disease, detection of seedlings with the pathogen and breeding of diseaseresistant Areca palm varieties.

Platelet-Derived Growth Factor Receptor-α Subunit Targeting Suppresses Metastasis in Advanced Thyroid Cancer In Vitro and In Vivo

( Ching-ling Lin ),( Ming-lin Tsai ),( Yu-hsin Chen ),( Wei-ni Liu ),( Chun-yu Lin ),( Kai-wen Hsu ),( Chien-yu Huang ),( Yu-jia Chang ),( Po-li Wei ),( Shu-huey Chen ),( Li-chi Huang ),( Chia-hwa Lee 한국응용약물학회 2021 Biomolecules & Therapeutics(구 응용약물학회지) Vol.29 No.5

Thyroid cancer is the most common endocrine malignancy. Patients with well-differentiated thyroid cancers, such as papillary and follicular cancers, have a favorable prognosis. However, poorly differentiated thyroid cancers, such as medullary, squamous and anaplastic advanced thyroid cancers, are very aggressive and insensitive to radioiodine treatment. Thus, novel therapies that attenuate metastasis are urgently needed. We found that both PDGFC and PDGFRA are predominantly expressed in thyroid cancers and that the survival rate is significantly lower in patients with high PDGFRA expression. This finding indicates the important role of PDGF/PDGFR signaling in thyroid cancer development. Next, we established a SW579 squamous thyroid cancer cell line with 95.6% PDGFRA gene insertion and deletions (indels) through CRISPR/Cas9. Protein and invasion analysis showed a dramatic loss in EMT marker expression and metastatic ability. Furthermore, xenograft tumors derived from PDGFRA geneedited SW579 cells exhibited a minor decrease in tumor growth. However, distant lung metastasis was completely abolished upon PDGFRA gene editing, implying that PDGFRA could be an effective target to inhibit distant metastasis in advanced thyroid cancers. To translate this finding to the clinic, we used the most relevant multikinase inhibitor, imatinib, to inhibit PDGFRA signaling. The results showed that imatinib significantly suppressed cell growth, induced cell cycle arrest and cell death in SW579 cells. Our developed noninvasive apoptosis detection sensor (NIADS) indicated that imatinib induced cell apoptosis through caspase-3 activation. In conclusion, we believe that developing a specific and selective targeted therapy for PDGFRA would effectively suppress PDGFRA-mediated cancer aggressiveness in advanced thyroid cancers.